BACKGROUND: Insulin-like growth factor-1 receptor (IGF-1R) is implicated in the pathogenesis of rhabdomyosarcoma (RMS), osteosarcoma (OS), and synovial sarcoma (SS). The authors conducted a multi-institutional phase 2 trial of the monoclonal antibody R1507 in patients with various subtypes of recurrent or refractory sarcomas. METHODS: Eligibility criteria included age ≥ 2 years and a diagnosis of recurrent or refractory RMS, OS, SS, and other soft tissue sarcomas. Patients received a weekly dose of 9 mg/kg R1507 intravenously. The primary endpoint was the best objective response rate using World Health Organization criteria. Tumor imaging was performed every 6 weeks × 4 and every 12 weeks thereafter. RESULTS: From December 2007 through August 2009, 163 eligible patients from 33 institutions were enrolled. The median patient age was 31 years (range, 7-85 years). Histologic diagnoses included OS (n = 38), RMS (n = 36), SS (n = 23), and other sarcomas (n = 66). The overall objective response rate was 2.5% (95% confidence interval, 0.7%-6.2%). Partial responses were observed in 4 patients, including 2 patients with OS, 1 patient with RMS, and 1 patient with alveolar soft part sarcoma. Four additional patients (3 with RMS and 1 with myxoid liposarcoma) had a ≥ 50% decrease in tumor size that lasted for <4 weeks. The median progression-free survival was 5.7 weeks, and the median overall survival was 11 months. The most common grade 3/4 toxicities were metabolic (12%), hematologic (6%), gastrointestinal (4%), and general constitutional symptoms (8%). CONCLUSIONS: R1507 is safe and well tolerated but has limited activity in patients with recurrent or refractory bone and soft tissue sarcomas. Additional studies to help identify the predictive factors associated with clinical benefit in selected histologies such as RMS appear to be warranted.
BACKGROUND:Insulin-like growth factor-1 receptor (IGF-1R) is implicated in the pathogenesis of rhabdomyosarcoma (RMS), osteosarcoma (OS), and synovial sarcoma (SS). The authors conducted a multi-institutional phase 2 trial of the monoclonal antibody R1507 in patients with various subtypes of recurrent or refractory sarcomas. METHODS: Eligibility criteria included age ≥ 2 years and a diagnosis of recurrent or refractory RMS, OS, SS, and other soft tissue sarcomas. Patients received a weekly dose of 9 mg/kg R1507 intravenously. The primary endpoint was the best objective response rate using World Health Organization criteria. Tumor imaging was performed every 6 weeks × 4 and every 12 weeks thereafter. RESULTS: From December 2007 through August 2009, 163 eligible patients from 33 institutions were enrolled. The median patient age was 31 years (range, 7-85 years). Histologic diagnoses included OS (n = 38), RMS (n = 36), SS (n = 23), and other sarcomas (n = 66). The overall objective response rate was 2.5% (95% confidence interval, 0.7%-6.2%). Partial responses were observed in 4 patients, including 2 patients with OS, 1 patient with RMS, and 1 patient with alveolar soft part sarcoma. Four additional patients (3 with RMS and 1 with myxoid liposarcoma) had a ≥ 50% decrease in tumor size that lasted for <4 weeks. The median progression-free survival was 5.7 weeks, and the median overall survival was 11 months. The most common grade 3/4 toxicities were metabolic (12%), hematologic (6%), gastrointestinal (4%), and general constitutional symptoms (8%). CONCLUSIONS: R1507 is safe and well tolerated but has limited activity in patients with recurrent or refractory bone and soft tissue sarcomas. Additional studies to help identify the predictive factors associated with clinical benefit in selected histologies such as RMS appear to be warranted.
Authors: Aung Naing; Razelle Kurzrock; Angelika Burger; Sachin Gupta; Xiudong Lei; Naifa Busaidy; David Hong; Helen X Chen; Lawrence A Doyle; Lance K Heilbrun; Eric Rohren; Chaan Ng; Chandtip Chandhasin; Patricia LoRusso Journal: Clin Cancer Res Date: 2011-07-12 Impact factor: 12.531
Authors: Francesco Atzori; Josep Tabernero; Andrés Cervantes; Ludmila Prudkin; Jordi Andreu; Edith Rodríguez-Braun; Amparo Domingo; Jorge Guijarro; Cristina Gamez; Jordi Rodon; Serena Di Cosimo; Holly Brown; Jason Clark; James S Hardwick; Robert A Beckman; William D Hanley; Karl Hsu; Emiliano Calvo; Susana Roselló; Ronald B Langdon; José Baselga Journal: Clin Cancer Res Date: 2011-08-02 Impact factor: 12.531
Authors: Jinu Abraham; Suresh I Prajapati; Koichi Nishijo; Beverly S Schaffer; Eri Taniguchi; Aoife Kilcoyne; Amanda T McCleish; Laura D Nelon; Francis G Giles; Argiris Efstratiadis; Robin D LeGallo; Brent M Nowak; Brian P Rubin; Suman Malempati; Charles Keller Journal: Mol Cancer Ther Date: 2011-03-29 Impact factor: 6.261
Authors: Emmy D G Fleuren; Yvonne M H Versleijen-Jonkers; Addy C M van de Luijtgaarden; Janneke D M Molkenboer-Kuenen; Sandra Heskamp; Melissa H S Roeffen; Hanneke W M van Laarhoven; Peter J Houghton; Wim J G Oyen; Otto C Boerman; Winette T A van der Graaf Journal: Clin Cancer Res Date: 2011-10-28 Impact factor: 12.531
Authors: Vivek Subbiah; Aung Naing; Robert E Brown; Helen Chen; Laurence Doyle; Patricia LoRusso; Robert Benjamin; Pete Anderson; Razelle Kurzrock Journal: PLoS One Date: 2011-04-06 Impact factor: 3.240
Authors: Simone Hettmer; Zhizhong Li; Andrew N Billin; Frederic G Barr; D D W Cornelison; Alan R Ehrlich; Denis C Guttridge; Andrea Hayes-Jordan; Lee J Helman; Peter J Houghton; Javed Khan; David M Langenau; Corinne M Linardic; Ranadip Pal; Terence A Partridge; Grace K Pavlath; Rossella Rota; Beat W Schäfer; Janet Shipley; Bruce Stillman; Leonard H Wexler; Amy J Wagers; Charles Keller Journal: Cold Spring Harb Perspect Med Date: 2014-11-03 Impact factor: 6.915
Authors: Lillian M Guenther; Neekesh V Dharia; Linda Ross; Amy Conway; Amanda L Robichaud; Jerrel L Catlett; Caroline S Wechsler; Elizabeth S Frank; Amy Goodale; Alanna J Church; Yuen-Yi Tseng; Rajarshi Guha; Crystal G McKnight; Katherine A Janeway; Jesse S Boehm; Jaume Mora; Mindy I Davis; Gabriela Alexe; Federica Piccioni; Kimberly Stegmaier Journal: Clin Cancer Res Date: 2018-11-05 Impact factor: 12.531
Authors: Marielle E Yohe; Christine M Heske; Elizabeth Stewart; Peter C Adamson; Nabil Ahmed; Cristina R Antonescu; Eleanor Chen; Natalie Collins; Alan Ehrlich; Rene L Galindo; Berkley E Gryder; Heidi Hahn; Sharon Hammond; Mark E Hatley; Douglas S Hawkins; Madeline N Hayes; Andrea Hayes-Jordan; Lee J Helman; Simone Hettmer; Myron S Ignatius; Charles Keller; Javed Khan; David G Kirsch; Corinne M Linardic; Philip J Lupo; Rossella Rota; Jack F Shern; Janet Shipley; Sivasish Sindiri; Stephen J Tapscott; Christopher R Vakoc; Leonard H Wexler; David M Langenau Journal: Pediatr Blood Cancer Date: 2019-06-21 Impact factor: 3.167
Authors: Catalina Ruiz-Mesa; John M Goldberg; Alvaro J Coronado Munoz; Sarah N Dumont; Jonathan C Trent Journal: Curr Treat Options Oncol Date: 2015-06
Authors: Brendan Murphy; Han Yin; John M Maris; E Anders Kolb; Richard Gorlick; C Patrick Reynolds; Min H Kang; Stephen T Keir; Raushan T Kurmasheva; Igor Dvorchik; Jianrong Wu; Catherine A Billups; Nana Boateng; Malcolm A Smith; Richard B Lock; Peter J Houghton Journal: Cancer Res Date: 2016-08-05 Impact factor: 12.701
Authors: Shuai Ye; Matthew A Lawlor; Adrian Rivera-Reyes; Shaun Egolf; Susan Chor; Koreana Pak; Gabrielle E Ciotti; Avery C Lee; Gloria E Marino; Jennifer Shah; David Niedzwicki; Kristy Weber; Paul M C Park; Md Zahidul Alam; Alison Grazioli; Malay Haldar; Mousheng Xu; Jennifer A Perry; Jun Qi; T S Karin Eisinger-Mathason Journal: Cancer Res Date: 2018-02-28 Impact factor: 12.701